0. DOCID:2829 SCORE: 0.00686369620653497
DOCNO: 1146724
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: metabolism
AUTHOR: J G Bieri JG
AUTHOR: R P Evarts RP
PUBTYPE: Journal Article
JOURNALTITLE: The American journal of clinical nutrition.
COUNTRY: UNITED STATES
TITLE: Tocopherols and polyunsaturated fatty acids in human tissues.
PUBDATE: 19750701
Five tissues from three adults who died suddenly and three adult cancer victims were analyzed for alpha- and gamma-tocopherols and fatty acids. When compared with two reports in 1949 and 1958, the three presumably normal subjects had alpha-tocopherol concentrations in liver, muscle and adipose tissue in about the same range as earlier, but heart was twice as high and lung was three times higher than earlier. The content of gamma-tocopherol in all tissues was considerably higher than in 1949 or 1958. Tissues from cancer patients were no lower in alpha-tocopherol than tissues from normal subjects. Adipose tissue from three of the six subjects contained linoleic acid exceeding 15 per cent of total fatty acids. Tocopherols in these subjects, expressed on a tissue weight or tissue lipid basis, were not remarkable. The molar ratio of polyunsaturated fatty acids to alpha-tocopherol in heart and lung was calculated and its possible use in evaluating vitamin E status is discussed.


1. DOCID:7313 SCORE: 0.00629936914972148
DOCNO: 7427908
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: administration & dosage
QUALIFIER: administration & dosage
QUALIFIER: administration & dosage
QUALIFIER: drug therapy
AUTHOR: F P Smith FP
AUTHOR: D F Hoth DF
AUTHOR: B Levin B
AUTHOR: D A Karlin DA
AUTHOR: J S MacDonald JS
AUTHOR: P V Woolley PV
AUTHOR: P S Schein PS
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
PUBDATE: 19801101
Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM). Twenty-seven of these patients had measurable disease, and ten (37%) achieved a partial response. An additional three patients had evidence of disease stabilization. The median survival period of responding patients was 12 months, compared with 3.5 months for nonresponders (P < 0.01). The median survival period for all patients was 6 months. Moderate myelosuppression constituted the treatment-limiting toxicity. The FAM combination is an active and well-tolerated regimen for pancreatic cancer and may have an application in the management of patients with less advanced disease.


2. DOCID:7929 SCORE: 0.00589635878212896
DOCNO: 103610
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: administration & dosage
QUALIFIER: drug therapy
AUTHOR: M Perloff M
AUTHOR: R D Hart RD
AUTHOR: J F Holland JF
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy.
PUBDATE: 19781201
Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combinations of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow-up of 10 months. Only 2/10 responders have died with a mean follow-up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither influenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease.


3. DOCID:3120 SCORE: 0.00586074649643751
DOCNO: 612703
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Antineoplastic Agents
QUALIFIER: pharmacology
AUTHOR: T Aoyagi T
AUTHOR: M Ishizuka M
AUTHOR: T Takeuchi T
AUTHOR: H Umezawa H
PUBTYPE: Journal Article
JOURNALTITLE: The Japanese journal of antibiotics.
COUNTRY: JAPAN
TITLE: Enzyme inhibitors in relation to cancer therapy.
PUBDATE: 19771201
In the last 11 years the authors have succeeded in isolating nearly 40 enzyme inhibitors of small molecular size from microbial origins. These inhibitors proved to be not only useful tools in analyses of homeostasis of living organisms but also promising agents for cancer chemotherapy. Leupeptin was originally isolated as an inhibitor against serine or thiol proteases such as trypsin, plasmin, papain and cathepsin B. And soon it was demonstrated that leupeptin suppressed chemical carcinogenesis in rats. Pepstatin has an extremely strong activity to inhibit pepsin and cathepsin D. It also inhibits ascites accumulation caused by neoplastic diseases. Bestatin is a specific inhibitor against aminopeptidase B and leucine aminopeptidase. The enzymes are located on the surface membrane in various kinds of cells including lymphocytes. Bestatin was shown to enhance not only blastogenesis of lymphocytes in vitro but also establishment of delayed-type hypersensitivity in vivo. Combined use of bestatin and other antitumor agents gave promising results in animal experiments. Studies on enzyme inhibitors have provided us a new approach to cancer chemotherapy.


4. DOCID:3038 SCORE: 0.00573825056103966
DOCNO: 187259
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Herpesviridae
DESCRIPTOR: Oncogenic Viruses
AUTHOR: D V Ablashi DV
AUTHOR: J M Easton JM
AUTHOR: J H Guegan JH
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Biomedicine / [publiée pour l'A.A.I.C.I.G.].
COUNTRY: FRANCE
TITLE: Herpesviruses and cancer in man and subhuman primates.
PUBDATE: 19761101
Because there is strong evidence for the involvement of Epstein-Barr virus in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma, we have discussed the relationship of Epstein-Barr virus to these two diseases in the context of geographic distribution, pathology, epidemiology, genetics, immunovirology, and biochemistry. We have also discussed the relationship of Epstein-Barr virus to other diseases, both malignant and non-malignant. Although the etiologic relationship of herpes simplex virus type 2 to squamous carcinoma of the uterine cervix is not on as firm ground, we feel that some good evidence does exist. We have also discussed two oncogenic simian viruses, Herpesvirus saimiri and Herpesvirus ateles. These have a great number of similarities to EBV, and thus may provide models for the study of viral-induced oncogenesis in man. Agents similar to Epstein-Barr virus have been isolated from old world monkeys. These may possibly be of greater importance than either Herpesvirus saimiri or Herpesvirus ateles in the investigation of human virally-induced cancers.


5. DOCID:3819 SCORE: 0.00568475800127266
DOCNO: 187314
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: therapeutic use
AUTHOR: M J Straus MJ
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Combination chemotherapy in advanced lung cancer with increased survival.
PUBDATE: 19761201
Twenty-eight patients with lung cancer, 26 with extensive disease, were treated with the drugs Cytoxan (Cyt) and methotrexate (MTX). The schedule was based on cellular kinetics concepts. Initial therapy was with Cyt 1.1 g/m2 (intravenously) followed by MTX 20 mg/m2 orally, twice weekly, started 9 days later, when the tumor was considered to be most susceptible to an S-phase-specific drug. The course was repeated at three-week intervals. Based on dose response curves, Cyt and MTX dose modifications were individually adjusted to the whit blood cell counts and platelet counts over a 3-week period. Twenty of 28 patients (five of seven large cell, five of eight adenocarcinoma, 10 or 11 small cell, none of two epidermoid) responded with greater than or equal 50% tumor reduction. Ten patients had complete responses, seven of whom had small cell carcinoma. Two of the nonresponders were nonevaluable. Five patients were alive and the extimated median survival time of the patients is almost 1 year, which compares quite favorably to previous reports. On this schedule of therapy, very high doses of Cyt and MTX were maintained with less than 3% incidence per course of a WBC less than 1,500/mm3 or a platelet count less than 50,000/mm3.


6. DOCID:3405 SCORE: 0.00530128179725896
DOCNO: 303021
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: methods
QUALIFIER: diagnosis
AUTHOR: W Weiss W
AUTHOR: H Hanak H
AUTHOR: A Huber A
PUBTYPE: Journal Article
JOURNALTITLE: Wiener klinische Wochenschrift.
COUNTRY: AUSTRIA
TITLE: [Clinical value of rectal digital examination in early diagnosis of colorectal cancer (author's transl)]
PUBDATE: 19771001
A prospective study was carried out on a series of 1500 patients of a gastro-enterological and surgical unit in order to evaluate critically the accuracy of rectal digital examination as a single tool in the early diagnosis of colorectal tumours. The patients in this study were explored independently by two investigators, first by rectal digital palpation and afterwards by means of the proctosigmoidoscope. Endoscopy confirmed the presence of 239 tumours, 96 of these being diagnosed histologically as carcinoma. Comparative analysis of the results of physical and endoscopic examination demonstrated that digital palpation provided a correct diagnosis in 58 out of 239 tumours, equivalent to an accuracy of 24.3% for tumours within the reach of the rectoscope, and 10% for all colorectal tumours. Hence, rectal examination should not be used as single diagnostic tool in screening for large bowel cancer. A multiphasic screening system, including investigations for occult blood, proctosigmoidoscopy, endoscopic polypectomy and determination of colon-embryonic-antigen levels is discussed to obtain better results in general health screening, early diagnosis and avoidance of incurable colorectal carcinomas and the early detection of recurrence.


7. DOCID:3904 SCORE: 0.0052664805279954
DOCNO: 1228090
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
AUTHOR: G K Döring GK
PUBTYPE: Journal Article
JOURNALTITLE: Fortschritte der Medizin.
COUNTRY: GERMANY, WEST
TITLE: [Side-effects of ovulation inhibitors]
PUBDATE: 19751001
The discussion about the side-effects of oral contraceptives received new aspects through the publication of the prospective British Study "Oral Contraceptives and Health" (by the Royal College of General Practitioners) in 1974. This article is divided into the following sections: Beneficial side-effects (elimination of symptoms in dysmenorrhea, endometriosis, acne vulgaris, menorrhagia and anemia). Harmless side-effects (harmless symptoms not implying illness). Clinically important side-effects (menstrual disorders, facilitation of moniliasis and trichomoniasis, diseases of the circulatory system, thrombo-embolism). Oral contraceptives have no adverse effects on the fertility of women. Significant is the conclusion that pregnancy and children are normal after the use of oral contraceptives. There are no indications of an increased risk of cancer. The results of the British study confirm a reduced incidence of benign breast tumors in women using oral contraceptives. The suggestion to select a pill-type considering the hormonal constitution of a woman did not prove to be of help. The original proposal of changing the pill-type according to the observed side-effects therefore remains valid. A classification of the used oral contraceptives into the groups "with gestagen accentuation", "hormonally balanced" and "with estrogen accentuation" will help the physician to prescribe the most useful type. An extensive table summarizes the most frequent side-effects, explains their causes and recommends ways of eliminating the symptoms by changing the pill-type.


8. DOCID:3777 SCORE: 0.0052379944847103
DOCNO: 892932
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Anesthesia, Inhalation
DESCRIPTOR: Ether, Ethyl
DESCRIPTOR: Ethyl Ethers
DESCRIPTOR: Halothane
QUALIFIER: mortality
AUTHOR: I A Fried IA
PUBTYPE: Journal Article
JOURNALTITLE: International journal of cancer. Journal international du cancer.
COUNTRY: DENMARK
TITLE: The influence of the anaesthetic on survival rates of breast cancer patients after surgery.
PUBDATE: 19770801
The end results of therapy of 1,358 breast cancer patients were studied. Anaesthesia was performed by ether-nitrogen-oxygen (554 cases) or halothane-nitrogen-oxygen (804 cases) mixture with addition of oxygen. The method of Holstead was employed in all cases. A comparison of groups of patients on the basis of such parameters as the anaesthetic used, age and degree of tumour progression (according to the TNM classification and results of post-operative histological assays) showed them to be identical. The study showed that the type of anaesthesia influenced the end results of therapy of cancer patients: the survival rates of patients receiving halothane anaesthesia were much higher than those of the ether-anaesthetized patients. The differences were most pronounced among patients who received pre-operative radiation therapy and post-operative chemotherapy as well as in cases of metastasis spread into regional lymph nodes. The mechanism of the effect of the anaesthetic on the survival rates of cancer patients may be explained on the basis of the data available on the varying influences of anaesthetics on the pituitary-adrenal cortec system and carcinemia development during operation as well as the role of immunity in tumour cell implantation and growth of metastases.


9. DOCID:6770 SCORE: 0.00499852991981668
DOCNO: 6245096
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Protons
QUALIFIER: methods
AUTHOR: H D Suit HD
AUTHOR: M Goitein M
AUTHOR: J E Munzenrider JE
AUTHOR: L Verhey L
AUTHOR: E Gragoudas E
AUTHOR: A M Koehler AM
AUTHOR: M Urano M
AUTHOR: W U Shipley WU
AUTHOR: R M Linggood RM
AUTHOR: C Friedberg C
AUTHOR: M Wagner M
PUBTYPE: Journal Article
JOURNALTITLE: Journal of the Canadian Association of Radiologists.
COUNTRY: CANADA
TITLE: Clinical experience with proton beam radiation therapy.
PUBDATE: 19800301
Our experience with modulated energy proton beams in the definitive treatment of cancer patients indicates that, for the patients accepted, treatment volumes have been smaller and total doses higher than would have obtained for photon techniques alone used in our institution. The reactions of normal tissue have, with very few exceptions, been readily acceptable. The higher radiation doses employed should yield higher tumor control frequencies. Clearly, we cannot assess the efficacy of this modality because of the small number of patients followed for short periods. However, the results are judged by use to warrant intensive evaluation of this modality.


10. DOCID:3608 SCORE: 0.00499126369362766
DOCNO: 1030678
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: enzymology
QUALIFIER: enzymology
QUALIFIER: enzymology
QUALIFIER: isolation & purification
AUTHOR: H Nawata H
AUTHOR: K I Kato KI
AUTHOR: H Ibayashi H
PUBTYPE: Journal Article
JOURNALTITLE: Gann = Gan.
COUNTRY: JAPAN
TITLE: Properties of thymidine kinase partially purified from human adrenal glands.
PUBDATE: 19760801
Thymidine kinase was partially purified from human adrenocortical carcinoma, hyperplasia, and normal adrenal glands. For the purpose of clarifying the qualitative and quantitative difference of thymidine kinase between cancer and normal tissue, biochemical properties of partially purified thymidine kinase were compared. Adrenocortical carcinoma and hyperplasia contained greater concentration of thymidine kinase than normal adrenal gland. By the DEAE-cellulose chromatography, adrenocortical carcinoma gave two peaks (Peak I and Peak II) of thymidine kinase, while in hyperplasia and normal adrenal gland, the second peak (Peak II) was only slightly detected or hardly detected. Thymidine kinase in these three glands was identical with respect to pH optimum and inhibition by dTTP, but inhibition by dCTP was quite different. dCTP inhibited the activity of normal adrenal gland and Peak II of adrenocortical carcinoma by 55% and 40% at 0.1 mM, respectively, but the activity of adrenocortical hyperplasia and Peak I of adrenocortical carcinoma was hardly affected. Normal adrenal enzyme was more stable against heat inactivation than adrenocortical carcinoma and hyperplasia. The apparent Km with thymidine for Peak I and Peak II of adrenocortical carcinoma, hyperplasia, and normal adrenal gland was 5.0, 11.1, 5.1 and 25.0 x 10(-6)M, respectively.


11. DOCID:5249 SCORE: 0.00474004251147637
DOCNO: 209161
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: mortality
AUTHOR: F P Li FP
AUTHOR: M H Myers MH
AUTHOR: H W Heise HW
AUTHOR: N Jaffe N
PUBTYPE: Journal Article
JOURNALTITLE: The Journal of pediatrics.
COUNTRY: UNITED STATES
TITLE: The course of five-year survivors of cancer in childhood.
PUBDATE: 19780801
A follow-up study was made of two independent series of 1,807 and 425 children who were alive five years after diagnosis of a malignant neoplasm. Over the subsequent 20 years (5 to 24 years after initial diagnosis), actuarial survival rates for the cohorts were 83% and 79%, respectively, compared to 97% for matched control subjects in the general population (P less than 0.01). Cure was achieved in a large majority of the 5-year relapse-free survivors of cancer in this study.


12. DOCID:7478 SCORE: 0.00462279153071926
DOCNO: 222425
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: metabolism
QUALIFIER: biosynthesis
QUALIFIER: metabolism
AUTHOR: M Hattori M
AUTHOR: H Imura H
AUTHOR: S Matsukura S
AUTHOR: Y Yoshimoto Y
AUTHOR: K Sekita K
AUTHOR: T Tomomatsu T
AUTHOR: M Kyogoku M
AUTHOR: T Kameya T
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Cancer.
COUNTRY: UNITED STATES
TITLE: Multiple-hormone producing lung carcinoma.
PUBDATE: 19790601
Endocrine and immunohistochemical studies were performed in a patient with lung cancer associated with gynecomastia. Elevated level of human chorionic gonadotropin (hCG) in plasma and mild hyperadrenocorticism were demonstrated by hormone assays. Postmortem examination proved the existence of anaplastic small cell carcinoma of the lung mixed with a feature of chorioepithelioma. The presence of significant amounts of adrenocorticotropic hormone (ACTH), beta-melanocyte stimulating hormone (beta-MSH), calcitonin, gastrin, hCG, hCG-alpha, hCG-beta and human chorionic somatomammotropin (hCS) in tumor tissues was demonstrated by radioimmunoassays, bioassay and immunohistochemical techniques. We present here a unique case of multiple hormones producing tumor elaborating both hormones of amine precursor uptake and decarboxylation (APUD) series (ACTH, beta-MSH, calcitonin and gastrin) and of placental origin (hCG, hCG-alpha, hCG-beta and hCS).


13. DOCID:3093 SCORE: 0.00441550386482665
DOCNO: 1251278
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
AUTHOR: J J van Dyk JJ
AUTHOR: A M van der Merwe AM
AUTHOR: H C Falkson HC
AUTHOR: G Falkson G
PUBTYPE: Journal Article
JOURNALTITLE: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
COUNTRY: SOUTH AFRICA
TITLE: Adriamycin in the treatment of cancer.
PUBDATE: 19760101
Adriamycin is a new anticancer antibiotic with a wide spectrum of activity against solid tumours. The results obtained with this agent in 159 patients with histologically confirmed advanced metastastic malignancies are reported. Encouraging results were obtained in patients with sarcomas of bone and soft tissue (12/22). Response was also seen in mesothelioma (3/9) and lung cancer (5/15). A variety of other neoplasms was also treated and results obtained in neuroblastoma, testicular tumours, stomach carcinoma, breast cancer and nephroblastoma are reported. Treatment is discussed, with reference to response rates and toxicity. Results in 72 patients with advanced breast cancer, who received adriamycin in combination with other chemotherapeutic agents, are presented. Seventeen patients with primary liver cancer were also treated with adriamycin. To date, this is the only chemotherapeutic agent that appears to significantly improve survival times in patients with this resistant form of cancer. The prophylactic use of adriamycin against osteogenic sarcoma is also discussed.


14. DOCID:3025 SCORE: 0.00435186928994574
DOCNO: 74302
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: drug therapy
AUTHOR: L A Price LA
AUTHOR: B T Hill BT
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
PUBTYPE: Randomized Controlled Trial
JOURNALTITLE: Clinical otolaryngology and allied sciences.
COUNTRY: ENGLAND
TITLE: A kinetically based logical approach to the chemotherapy of head and neck cancer.
PUBDATE: 19771101
The application of some basic principles derived from studies of the cell cycle and proliferative kinetics of normal and malignant cells has provided a rational basis for designing cancer treatment protocols. Using this approach in advanced head and neck cancer it is possible (a) to increase the response rate, (b) to reduce toxicity and (c) to reduce in-patient hospital stay time. Seventy-one patients with advanced carcinoma of the head and neck were randomized for treatment between two combination schedules, one with and the other without adriamycin. Responses (more than 50% tumour regression) were 74% overall with 70% responding to the combination without adriamycin and 82% responding to the schedule containing it. The increase in response rate seen with adriamycin is not statistically significant. Prior radiotherapy significantly reduced the likelihood of response to chemotherapy. These results have major implications for adjuvant chemotherapy and suggest a possible way of increasing the survival time in this group of diseases.